MicroRNA-21 coordinates human multipotent cardiovascular progenitors therapeutic potential

Stem Cells

Volumn 32, Issue 11, 2014, Pages 2908-2922

  Richart, Adèle ^a   Loyer, Xavier ^a   Néri, Tui ^b   Howangyin, Kiave ^a   Guérin, Coralie L ^a   Ngkelo, Anta ^a   Bakker, Wineke ^a   Zlatanova, Ivana ^a   Rouanet, Marie ^a   Vilar, José ^a   Lévy, Bernard ^a   Rothenberg, Marc ^c   Mallat, Ziad ^a   Pucéat, Michel ^b,d   Silvestre, Jean Sébastien ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b INSERM   (France)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiogenesis; Inflammation; Ischemia; MicroRNA; Stem cells

Indexed keywords

MICRORNAS; MIRN21 MICRORNA, HUMAN; MIRN21 MICRORNA, MOUSE;

ANIMALS; BLOOD SUPPLY; CELL LINEAGE; CELL SURVIVAL; GENETICS; HINDLIMB; HUMANS; ISCHEMIA; METABOLISM; METHODS; MICE; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

ANIMALS; CELL LINEAGE; CELL SURVIVAL; HINDLIMB; HUMANS; ISCHEMIA; MICE; MICRORNAS; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84907906593     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1789     Document Type: Article

References (55)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
2. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: Physiological and therapeutic perspectives. Circulation 2004; 109: 656-663.
3. Silvestre JS, Gojova A, Brun V, et al. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. Circulation 2003; 108: 2839-2842.
4. Aicher A, Rentsch M, Sasaki K, et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007; 100: 581-589.
5. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427.
6. Foubert P, Matrone G, Souttou B, et al. Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy. Circ Res 2008; 103: 751-760.
7. Campagnolo P, Cesselli D, Al Haj Zen A, et al. Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation 2010; 121: 1735-1745.
8. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427-435.
9. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circ J 2012; 76: 1750-1760.
10. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4: 26-37.
11. Fadini GP, Agostini C, Avogaro A,. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209: 10-17.
12. Dimmeler S, Leri A,. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008; 102: 1319-1330.
13. Teraa M, Sprengers RW, Westerweel PE, et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS One 2013; 8: e55592.
14. Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: A phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009; 27: 2857-2864.
15. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004; 109: 1615-1622.
16. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, et al. Impairment in ischemia-induced neovascularization in diabetes: Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol 2004; 164: 457-466.
17. Mees B, Recalde A, Loinard C, et al. Endothelial nitric oxide synthase overexpression restores the efficiency of bone marrow mononuclear cell-based therapy. Am J Pathol 2011; 178: 55-60.
18. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
19. Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 2000; 6: 88-95.
20. Puceat M,. Could a pluripotent stem cell give rise to a high yield of a single cell lineage: A myocardial cell? Curr Opin Genet Dev 2013; 23: 498-499.
21. Roy NS, Cleren C, Singh SK, et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006; 12: 1259-1268.
22. Lai WH, Ho JC, Chan YC, et al. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. PLoS One 2013; 8: e57876.
23. Yamahara K, Sone M, Itoh H, et al. Augmentation of neovascularization [corrected] in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One 2008; 3: e1666.
24. Moon SH, Kim JS, Park SJ, et al. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. Biomaterials 2011; 32: 6445-6455.
25. Blin G, Nury D, Stefanovic S, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010; 120: 1125-1139.
26. Heinrich EM, Dimmeler S,. MicroRNAs and stem cells: Control of pluripotency, reprogramming, and lineage commitment. Circ Res 2012; 110: 1014-1022.
27. Kane NM, Howard L, Descamps B, et al. Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells 2012; 30: 643-654.
28. Kane NM, Thrasher AJ, Angelini GD, et al. Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells 2014; 32: 1059-1066.
29. Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol 2011; 187: 3362-3373.
30. Loinard C, Ginouves A, Vilar J, et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 2009; 120: 50-59.
31. Loinard C, Zouggari Y, Rueda P, et al. C/EBP homologous protein-10 (CHOP-10) limits postnatal neovascularization through control of endothelial nitric oxide synthase gene expression. Circulation 2012; 125: 1014-1026.
32. Smadja DM, d'Audigier C, Guerin CL, et al. Angiogenic potential of BM MSCs derived from patients with critical leg ischemia. Bone Marrow Transplant 2012; 47: 997-1000.
33. Voellenkle C, Rooij J, Guffanti A, et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 2012; 18: 472-484.
34. Kuehbacher A, Urbich C, Zeiher AM, et al. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101: 59-68.
35. Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011; 6: e19139.
36. Bao B, Ali S, Ahmad A, et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 2012; 7: e50165.
37. Guduric-Fuchs J, O'Connor A, Cullen A, et al. Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells. J Cell Biochem 2012; 113: 2098-2111.
38. Di Bernardini E, Campagnolo P, Margariti A, et al. Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor beta2 (TGF-beta2) pathways. J Biol Chem 2014; 289: 3383-3393.
39. Zhao D, Tu Y, Wan L, et al. In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging. PLoS One 2013; 8: e71472.
40. Silvestre JS, Smadja DM, Levy BI,. Postischemic revascularization: From cellular and molecular mechanisms to clinical applications. Physiol Rev 2013; 93: 1743-1802.
41. Patterson M, Chan DN, Ha I, et al. Defining the nature of human pluripotent stem cell progeny. Cell Res 2012; 22: 178-193.
42. Hendrix MJ, Seftor EA, Hess AR, et al. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
43. Lee MJ, Kim J, Lee KI, et al. Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells. Cytotherapy 2011; 13: 165-178.
44. Fleissner F, Jazbutyte V, Fiedler J, et al. Short communication: Asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 2010; 107: 138-143.
45. Zhu S, Deng S, Ma Q, et al. MicroRNA-10A∗ and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2. Circ Res 2013; 112: 152-164.
46. Treguer K, Heinrich EM, Ohtani K, et al. Role of the microRNA-17-92 cluster in the endothelial differentiation of stem cells. J Vasc Res 2012; 49: 447-460.
47. Small EM, Olson EN,. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011; 469: 336-342.
48. Choi WY, Giraldez AJ, Schier AF,. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 2007; 318: 271-274.
49. Lu TX, Lim EJ, Itskovich S, et al. Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth. PLoS One 2013; 8: e59397.
50. Tu Y, Wan L, Fan Y, et al. Ischemic postconditioning-mediated miRNA-21 protects against cardiac ischemia/reperfusion injury via PTEN/Akt pathway. PLoS One 2013; 8: e75872.
51. Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010; 120: 3912-3916.
52. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
53. Wang T, Feng Y, Sun H, et al. miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am J Pathol 2012; 181: 1911-1920.
54. Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 2011; 6: e16979.
55. Colucci F, Soudais C, Rosmaraki E, et al. Dissecting NK cell development using a novel alymphoid mouse model: Investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol 1999; 162: 2761-2765.